For drug discovery and development scientists, Eurofins DiscoverX is the trusted product solutions provider that can accelerate your programs with confidence with qualified reagents, cell lines, and assays ready to run today.
Eurofins DiscoverX develops and manufactures cutting edge assays, stable cell lines, membrane preps, enzymes, and reagents for drug discovery and development from our 3 R&D and manufacturing centers of excellence – San Francisco Bay Area California; St. Louis, Missouri; and Poitiers, France.
Rediscover how Eurofins DiscoverX expertise and trusted products accelerate your programs and enable you to take your drug to the next phase with confidence. With end-to-end support every step of the way for your programs from Discovery to QC lot release.
The CD47|SIRPα Summit Goes Online for 2020
Targeted Cancer R&D has been rocked by Covid-19 but as an industry, we cannot afford to put things on hold.
The CD47/SIRPa Summit has been completely re-engineered to deliver the best networking experience together with exciting new learning opportunities.
The agenda is purposely built to provide an engaging and interactive learning experience. Through integrated polls, open discussions, Q&A with speakers, and more, you will be able to accelerate your knowledge of the CD47/SIRPa axis in just two days. The ability to actively or passively be involved in these learning opportunities is yours!
Replicate those all-important ‘water cooler’ moments through randomly assigned networking or join custom-built sessions to find those with similar interests to you. Scroll through the entire attendee list to message your fellow attendees, schedule 1-2-1 video calls, or create your own private session rooms for group discussions. The CD47/SIRPa Summit will enable you to meet more leaders from across the industry than ever before!
The Digital Platform lets you create your own personal agenda. You can attend live sessions, take part in open networking sessions, or take a break whenever suits you. Seamlessly hop between learning and networking at any time. Look through the program and slot sessions directly into your calendar, to help fit the conference around the day job. All of this from the comfort of your own home.
With very promising results from the first clinical studies, the dedicated CD47/SIRPα Summit is perfectly timed. This event provides the opportunity for those who have pioneered the space and also the newcomers of the industry, to get together and learn more about this exciting and dynamic field.
The CD47/SIRPα Summit is a valuable opportunity to share our learnings and explore important questions about targeting the Myeloid Checkpoint pathway for the treatment of cancer.
Kipp Weiskopf, M.D., Ph.D is a clinical fellow in Hematology and Oncology at the Dana-Farber Cancer Institute in Boston, MA. He earned his medical and graduate degrees at Stanford University in the Medical Scientist Training Program. As a member of the laboratory of Irving Weissman, M.D., he characterized the CD47/SIRPα interaction as a myeloid immune checkpoint. He developed engineered SIRPα variants that augment macrophage phagocytosis of cancer and serve as universal enhancers of tumor-opsonizing therapeutic antibodies. He further demonstrated that CD47-blocking therapies can be effective for small cell lung cancer and that CD47-blocking therapies can permit bone marrow transplantation without chemotherapy or radiation. Weiskopf has also developed anti-SIRPα antibodies and showed they enhance phagocytosis in response to tumor-opsonizing antibodies. He further demonstrated that the CD47/SIRPa axis is conserved across evolutionary barriers. More recently, he identified a role for MHC class I molecules as regulators of macrophage activation. Weiskopf is a co-Founder of ALX Oncology, and technology he developed has been licensed to Forty Seven, Inc.
Weiskopf completed his medical training in Internal Medicine Residency Program at Brigham and Women’s Hospital in Boston. He has been awarded the Winston Churchill Scholarship, an NCI Ruth L. Kirschstein NRSA Fellowship, the Harold M. Weintraub Graduate Student Award, the Joanna M. Nicolay Melanoma Foundation Research Scholar Award, and first place in the 2013 Collegiate Inventors Competition. He delivered the PEGS 2018 Young Scientist Keynote address. His ongoing research interests lie in identifying novel myeloid immune checkpoints that regulate macrophage activation within the tumor microenvironment.
Dr. Pons previously served as Chief Scientific Officer and site head of Rinat (Pfizer), where he was responsible for portfolio delivery from idea to clinical development. He implemented the vision of a company unit following biology across therapeutic areas while generating advanced antibody technologies and turned Rinat into the center of cancer immunology for Pfizer. Dr. Pons is an inventor of fremanezumab, which was approved by the FDA in 2018, as well as two other antibodies in late-stage clinical development and has advanced nine additional antibodies into human trials in multiple therapeutic areas. As Senior Vice President of R&D, he was a member of Pfizer’s World R&D Leadership Team. Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron. Dr. Pons earned his Ph.D. in molecular and cell biology at the Institute on Fundamental Biology, Barcelona, and an M.S. in biotechnology and B.S. in biochemistry from Autonoma University of Barcelona. He conducted his postdoctoral studies in antibody engineering at the University of California, Berkeley.
Timo Van Den Berg’s group was among the pioneering groups to describe cloning of the inhibitory receptor SIRPα and the first to describe its myeloid-restricted expression. His group have since been studying the physiological functions of CD47-SIRPα interactions and co-discovered, more or less together with the Weissman group at Stanford University, that its acts as an immune checkpoint in the context of antibody therapy in cancer. The method of interfering with the CD47-SIRPα innate immune checkpoint in combination with cancer-targeting monoclonal antibodies in cancer was successfully patented (WO2009/131453), and this was licensed to Synthon Biopharmaceuticals BV who they are collaborating with to develop agents targeting the CD47-SIRPα interaction.
Dr. Michal (Mikki) Tal is an instructor at Stanford University School of Medicine studying host-pathogen interactions with a focus on immune clearance and diversity of immune responses to tick-borne diseases. Michal received her PhD at Yale University in Immunobiology under the mentorship of Akiko Iwasaki. Dr Tal then did her postdoctoral training in the laboratory of Irving Weissman at Stanford where she is currently an instructor leading the infectious disease team and studying the immumodulatory mechanisms by which the CD47-SIRPa axis impacts immune clearance of infectious disease. Dr. Tal received the Yale Gershon Fellowship, NIH NIAID F31 and F32 pre and postdoctoral fellowships, was selected to give the inaugural Janeway early career lecture at Yale University, and awarded the Emerging Leader Award from Bay Area Lyme Foundation.
Nicolas Poirier earned his Ph.D. in Immunology at the European Center of Transplantation Sciences and Immunotherapy (CESTI) with guidance from immunotherapeutic-Transplant pioneer. He worked on the preclinical evaluation of novel therapeutic strategies modulating costimulation, immune checkpoint or complement pathways in preclinical models of transplantation and chronic inflammation. He received the awards “Prix de la Recherche Universitaire” by the French journal Le Monde and “New Key Opinion Leader” by the International Society of Transplantation. In 2009, he joined Effimune, a French biotechnology company specialized in immune regulation, where he led R&D programs for 7 years. Upon the merger of Effimune with OSE pharma in 2016, he was appointed Chief Scientific Officer of OSE Immunotherapeutics, a leading biotechnology company in the field of immune activation and regulation with clinical applications in immuno-oncology, autoimmune diseases and transplantation. As CSO, he supported the company’s growth and his R&D team is interested in identification, evaluation and development of innovative immunotherapies to establish, break, regulate or reinforce immune regulation and activation.
Dr. Mitra is currently an Assistant Professor of Pediatrics at the University of Colorado School of Medicine and the Children’s Hospital Colorado in the Division of Hematology-Oncology and Bone Marrow Transplant. His laboratory focuses on immune evasion mechanisms in Adult and Pediatric CNS Malignancies. He was part of the original CD47 disease team as a Senior Scientist at Stanford University.
Dr. Yaping Shou is the Chief Medical Officer of Trillium Therapeutics, a clinical-stage immune-oncology company developing innate immune checkpoint inhibitors. She has close to 20 years of industry experience spanning clinical development and translational medicine, with a strong focus in oncology. She most recently served as Executive Medical Director with Takeda Pharmaceuticals, and prior to joining Takeda, she held several clinical development positions with increasing responsibilities at Novartis Pharmaceuticals and GlaxoSmithKline. She received her MD from Zhejiang University School of Medicine and her PhD in Cellular and Molecular Biology from Drexel University College of Medicine and the University of Pennsylvania. She also conducted postdoctoral studies in the Genetics Branch at the National Cancer Institutes.
Taylor co-founded Shattuck Labs and is a member of the Board of Directors. Taylor is the lead inventor of Shattuck’s ARC technology platform.
Prior to Shattuck, Taylor served as Chief Scientific Officer of Heat Biologics, Inc. where he was a co-inventor of significant elements of Heat’s ImPACT and ComPACT technology platforms. He was also the co-inventor of TNFRSF25 agonist technology developed by Pelican Therapeutics, where he served as Chairman of the Scientific Advisory Board. Taylor has numerous publications in the field of tumor immunology and immunotherapy, spanning the subjects of cancer vaccines, therapeutic proteins and antibodies, adenosinergic and IDO mediated immunosuppression and regulatory T cell biology. In 2008, Taylor received the best overall research award at the National Student Research Forum and in 2011 he was nominated as a Future Leader in Cancer Research by the American Association for Cancer Research.
Taylor received his M.D. and Ph.D. degrees from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine. He received his B.A. in Biology from Bucknell University.
As CSO and a co-founder of I-Mab, Dr. Guo oversees Drug Discovery and Translational Medicine functions. He also leads scientific evaluation of potential business development deals. Prior to I-Mab, he worked on the discovery and development of novel drugs for neuro-inflammatory and neurodegenerative disorders at GlaxoSmithKline R&D for 8 years as leader or co-leader for 3 small molecule and 2 protein drug programs to up to phase I trials. He is particularly keen on developing facile and robust assays in order to drive rapid progression. For his contributions, he received a number of awards including the prestigious First-Time-in-Human award, Exceptional Science Awards twice, Best Team award as Leader (may be omitted).
Dr. Guo’s interest in drug research can be traced back to his undergraduate years in US where he got a pain research internship in the Department of Pharmacology in University of Iowa. He later moved on to the Division of Nephrology and the Division of Endocrinology at Harbor-UCLA Medical Center as a research associate. Dr. Guo has a PhD degree in immunology and a MSc degree in medical genetics from Shanghai Jiaotong University School of Medicine. He has published more than 35 papers in scientific journals.
Professor Matozaki is a pioneer researcher who first discovered SIRPα and has been working for the roles of the CD47-SIRPα system in various cell functions, particularly macrophages and dendritic cells for cancer immunity as well as autoimmunity.
After obtaining a PhD in pharmacology from SUNY Buffalo, NY, Limin worked on preclinical disease models for several years at Roswell Park Cancer Institute and Mount Sinai School of Medicine, NY. At Novimmune since 2009, he was involved in the preclinical development of several therapeutic antibody programs in autoimmunity and κλ body bispecific antibody programs in immuno-oncology.
In July 2019, Novimmune has been rebranded as “Light Chain Bioscience – A brand of Novimmune SA, and continues to work on novel bispecific technology and associated programs. As the director of pharmacology at Light Chain Bioscience, Limin is in charge of the pharmacological characterization of all bispecific antibody programs.
Dr. Claire Xu is the US Site Head of I-Mab Biopharma, a global biotech company exclusively focused on developing novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. She has built I-Mab’s US site at Rockville Maryland to a cross-functional clinical development team within 2 years and led the clinical development programs for all I-Mab global pipelines. Prior Joining I-Mab, she was a clinical pharmacologist focusing on Phase 1 clinical development at Otsuka Pharmaceutical Development & Commercialization for five years. Dr. Xu received her MD from Sun Yat-sen University and her PhD in Clinical Pharmacology from Indiana University School of Medicine.
André Veillette is a world-recognized scientist interested in signal transduction mechanisms in the immune system. Over the past two and a half decades, he has identified and characterized numerous intracellular molecules and receptors that play a crucial role in normal immune regulation.
Dr. Jane Lamerdin is the Director of R&D at Eurofins DiscoverX where she currently oversees the development of novel cell-based assays and tools to support portfolio expansion as well as client-focused projects. She has nearly 20 years of industry experience developing and prosecuting diverse cell-based assays to support client drug discovery campaigns, and high throughput, molecular and systems biology research. Prior to joining Eurofins DiscoverX, Jane was Executive Director of Research at Odyssey Thera, where she utilized her expertise in cell signaling pathways, oncology and DNA repair to guide the development of a broad panel of high content cell-based assays for compound safety and selectivity screening, which supported programs in major pharma companies as well as the ToxCast program at the EPA. Jane received her B.S. and Ph.D. in Genetics from the University of California at Davis; she is co-inventor on over 5 patents and has co-authored over 50 peer-reviewed articles.
Anthony Schwartz, Ph.D. is the Chief Executive Officer of Morphiex Biotherapeutics where he is leading efforts to move its SIRPa and thrombospondin-1 inhibitor through early-stage clinical trials. Before Morphiex, Anthony worked with the NIH/NCI to develop novel CD47 therapies for cancer. He’s founded over 10 companies, obtained FDA approval and pushed several drugs through IND studies. Anthony is also a professor at Johns Hopkins University.
Sebastian is a Co-founder and Managing Director of Scenic Biotech, and also holds an Adjunct Group leader and Associate Professor position at the Ludwig Institute for Cancer Research at Oxford University.
Sebastian obtained his PhD from The Netherlands Cancer Institute and was a postdoctoral fellow at the Broad Institute of Harvard and the M.I.T. He was group leader at the Research Center for Molecular Medicine in Vienna from 2007-2014 and is a member of the Young Academy of the Austrian Academy of Sciences. In 2010 he co-founded Haplogen GmbH and was its COO until 2014. At Haplogen, he initiated a partnership with Horizon Discovery, and co-led the subsequent $12Mio acquisition of Haplogen Genomics.
Stephanie Dougan received her PhD in Immunology from Harvard University. She then performed a postdoctoral fellowship with Hidde Ploegh at Whitehead Institute. Dr. Dougan joined the faculty at Harvard Medical School and Dana-Farber Cancer Institute in 2014, where her lab uses unique preclinical models to study the immune response to pancreatic cancer. She is particularly interested in why pancreatic cancer has been so refractory to immunotherapy, and has been developing new immunotherapies for this devastating disease. Dr. Dougan’s lab uses alpaca-derived antibodies to deliver cytokine-based immunotherapies to tumors, and uses an alpaca antibody against mouse CD47 to study the role of CD47 in syngeneic tumor models. Dr. Dougan is a Pew-Stewart Scholar in Cancer Research, a Bill and Melinda Gates Global Health Innovation Scholar, a Melanoma Research Alliance Young Investigator, and received a Pathway to Leadership Award from the Pancreatic Cancer Action Network and AACR. She is also dedicated to training young scientists, and received a Young Mentor Award from Harvard Medical School in 2019.
Dan Pereira, PhD, is Chief Scientific Officer at Arch Oncology, a privately held, clinical stage biotechnology company developing AO-176, a highly differentiated CD47 antibody, and advancing an immuno-oncology focused pipeline.
Prior to joining Arch Oncology, he served as Vice President, Discovery Research at Agensys/Astellas and before Agensys was Site Head and Vice President, Research at Arius/Hoffmann-La Roche Limited. Dr. Pereira began his industry career at ImClone Systems where he was Director, Tumor Biology.
Sergio Trombetta obtained his PharmD, PhD from the University of Buenos Aires and did postdoctoral research at Yale Medical School. He joined the Cancer immunology and Immune Modulation Program at Boehringer Ingelheim in 2017, where he has been developing novel immune therapies for oncology and inflammatory conditions.
Dr. Dougan is currently an Assistant Professor of Medicine at Massachusetts General Hospital and Harvard Medical School and is the Director of the Immunotherapy Mucosal Toxicities Program at Massachusetts General Hospital. He received his MD and PhD from Harvard Medical School. Dr. Dougan’s research focuses on the balance between antitumor responses and immune toxicities.
Dr. Cooney is a pediatric neuro-oncologist at Dana-Farber/Boston Children’s Cancer Center, and co-chair of the international Response Assessment in Pediatric Neuro-Oncology (RAPNO) DIPG committee. Her interests lie in the development and design of early phase pediatric CNS malignancy trials. She currently leads several multi-institutional trials through national and international pediatric oncology consortia.
Tim Zheng currently is the Executive Director of Immune Modulation at Boehringer Ingelheim. Tim received his PhD degree in Immunology at Yale in 1999, studying the roles of mammalian caspases using gene targeting. Following his training, Tim joined Biogen’s Immunology Research Department and during his 17 year’s tenure at Biogen, he studied extensively the role of cytokine signaling pathways in tissue inflammation and remodeling processes in both physiological and pathological settings, in particular those of the TNF superfamily members. Tim’s work at Biogen led to several IND filings of both biologics (anti-TWEAK & anti-OSMR mAbs) and small molecule drug candidates (Syk and Btk Inhibitors), as well as the successful BLA filing of Daclizumab (anti-CD25) in multiple sclerosis. Tim authored over 60 publications in peer reviewed journals and served on the study sections of both Arthritis Foundation and Scleroderma Research Foundation. Tim joined BI in 2016 to build and lead the Immune Modulation group in the US (Ridgefield, CT) to explore and exploit the full therapeutic potentials of immunomodulatory mechanisms in human diseases.
Dr. Zhengyi Wang is the co-founder and Executive Director of R&D in I-Mab Biopharma. He has taken on a leadership role in the antibody discovery and translational research in the company. Prior to joining I-Mab, Dr Wang worked for GSK R&D China in the early drug discovery targeting the neuro-inflammatory diseases. Dr Wang holds a Ph.D in immunology from the Chinese Academy of Sciences.
Andrew Pincetic is a Staff Scientist in the Immuno-Oncology department at Alector in South San Francisco, where he leads a team investigating the role of myeloid cells in oncology and neurodegeneration. His team is responsible for conducting mechanistic in vitro and in vivo studies to identify novel immune-targeted therapeutics. Dr. Pincetic holds a Ph.D. in Immunology from Northwestern University, where he studied innate immune response to viral infection, and he completed his postdoctoral studies in Fc-receptor biology at the Rockefeller University.
Digital Conference Platform
The Digital conference platform is purpose-built to enable us to provide you with a more personal experience.
For starters, no more wondering who is in the room! View and message the entire attendee list. If that’s not enough, there are a multitude of structured and unstructured networking opportunities to give you the chance to reconnect with old friends and meet your future collaborators.
Then there’s the learning. Through an engaging and interactive agenda, you will be able to actively or passively participate as much as you’d like. From polls and Q&A through to open discussions and dynamic panels, it has never been easier to accelerate your knowledge of the CD47/SIRPa axis.
Imagine the possibilities of this digital event! Networking with your peers, learning from the experts, collaborating, and shaping the future of the CD47/SIRPa industry – all on a world-class, purpose-built platform.
Partner With Us
The CD47/SIRPα Summit being online presents an opportunity for us to super-charge our offering. We have selected the best-in-class platform to offer our attendees a wide range of options to learn, network, and collaborate. The result, bringing together the senior R&D exec’s from across pharma and biotech.
Making your session engaging and knowledgeable will attract the largest audience. We will guide you on how best to maximize the benefits of using our platform.
No need to sit behind a desk! Our networking tools enable attendees to arrange 121 video conversations as well as taking part in curated networking sessions. You could potentially meet many more people than you would in a typical venue setting.
Get in touch to learn more about the options available at The CD47/SIRPα Summit.
Register for the Event
For pricing and booking options please click the button to go to the registration page.